Dutasteride and prostate cancer

2010-08-19

New England Journal of Medicine , Volume 363 - Issue 8 p. 793- 794

Additional Metadata
Keywords	aged, azasteroid, biopsy, blood, cancer diagnosis, cancer prevention, clinical practice, drug antagonism, dutasteride, enzyme inhibitor, human, letter, male, middle aged, note, pathology, prediction and forecasting, priority journal, prostate, prostate biopsy, prostate cancer, prostate hypertrophy, prostate specific antigen, prostate tumor, steroid 5alpha reductase
Persistent URL	dx.doi.org/10.1056/NEJMc1005498, hdl.handle.net/1765/20966
Journal	New England Journal of Medicine
Organisation	Erasmus MC: University Medical Center Rotterdam
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Schröder, F.H, & Roobol-Bouts, M.J. (2010). Dutasteride and prostate cancer. New England Journal of Medicine, 363(8), 793–794. doi:10.1056/NEJMc1005498

Publication